P/E ratio of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/E ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its earnings per share. A low P/E ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/E ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current P/E ratio of PHASEBIO PHARMA is 0.0 (as of December 30, 2020)
  • P/E ratio for the quarter ending June 29, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly P/E ratio decreased by NaN%
  • Annual P/E ratio for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual P/E ratio for 2019 was 0.0 (a NaN% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/E ratio of PHASEBIO PHARMA

Most recent P/E ratioof PHAS including historical data for past 10 years.

Interactive Chart of P/E ratio of PHASEBIO PHARMA

PHASEBIO PHARMA P/E ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0
2020 0.0 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0

Business Profile of PHASEBIO PHARMA

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.